

## Electronic Acknowledgement Receipt

<b>EFS ID:</b>	7429729
<b>Application Number:</b>	10821718
<b>International Application Number:</b>	
<b>Confirmation Number:</b>	1509
<b>Title of Invention:</b>	Hydrogels used to deliver medicaments to the eye for the treatment of posterior segment diseases
<b>First Named Inventor/Applicant Name:</b>	Clyde L. Schultz
<b>Customer Number:</b>	51886
<b>Filer:</b>	Stephen R. Finch/Elizabeth Cullity
<b>Filer Authorized By:</b>	Stephen R. Finch
<b>Attorney Docket Number:</b>	RH01.701US
<b>Receipt Date:</b>	16-APR-2010
<b>Filing Date:</b>	09-APR-2004
<b>Time Stamp:</b>	14:05:14
<b>Application Type:</b>	Utility under 35 USC 111(a)

### Payment information:

Submitted with Payment	yes
Payment Type	Credit Card
Payment was successfully received in RAM	\$ 180
RAM confirmation Number	308
Deposit Account	502121
Authorized User	FINCH,STEPHEN R

The Director of the USPTO is hereby authorized to charge indicated fees and credit any overpayment as follows:

Charge any Additional Fees required under 37 C.F.R. Section 1.16 (National application filing, search, and examination fees)

Charge any Additional Fees required under 37 C.F.R. Section 1.17 (Patent application and reexamination processing fees)

Charge any Additional Fees required under 37 C.F.R. Section 1.19 (Document supply fees)

Charge any Additional Fees required under 37 C.F.R. Section 1.20 (Post Issuance fees)

Charge any Additional Fees required under 37 C.F.R. Section 1.21 (Miscellaneous fees and charges)

## File Listing:

Document Number	Document Description	File Name	File Size(Bytes)/ Message Digest	Multi Part /.zip	Pages (if appl.)
1	Information Disclosure Statement (IDS) Filed (SB/08)	updated_IDS-temp2.pdf	614345	no	6
			b222d81fdc355d8b4be41d8332753c1e1a738d41		
Warnings:					
Information:					
2	Foreign Reference	WO03092665.pdf	1203420	no	39
			b63201d13d323c5f94616c1398a3b051da7056a6		
Warnings:					
Information:					
3	NPL Documents	Aiello-SuppressionofRetinalNeovascularizationinvivobyInhibitionofVascularEndothelial.pdf	1202450	no	5
			0b7c7165f13f554e8b9184f0928b89fc6ed03d31		
Warnings:					
Information:					
4	NPL Documents	Clark-AVascularEndothelialGrowthFactorAntagonistisProducedbytheHumanPlacenta.pdf	250904	no	9
			0b80e3c934973c871ebb105eed327ce01aabb18af		
Warnings:					
Information:					
5	NPL Documents	Duh-VascularEndothelialGrowthFactorandDiabetes.pdf	371645	no	8
			d1f55f103f3a015e7209fa9abb87bd94473867f4		
Warnings:					
Information:					
6	NPL Documents	Flieger-DramaticImprovementinHereditaryHemorrhagicTelangiectasiaAfterTreatment.pdf	42706	no	1
			cc7ea9c6c1eb6cf2bee559a8c245e36f93e9be6		
Warnings:					
Information:					
7	NPL Documents	Hazzard-InjectionofSolubleVascularEndothelialGrowthFactorReceptor1intothePreovulatory.pdf	837864	no	8
			71eedbdb9947d0ccc2489ecc990c432df9f05a2		
Warnings:					
Information:					
8	NPL Documents	Hetian-ANovelPeptidisolatedfromaPhageDisplayLibraryInhibitsTumorGrowthandMetastasis.pdf	433946	no	6
			bd40eb8aadcd25b1d643d6d1e0a5d007b84975e0		

Warnings:					
Information:					
9	NPL Documents	Inoue- Identification of a Vascular Endothelial Growth Factor-VEGF-Antagonist.pdf	306168	no	5
			d9e2fcd25e9b17eb2d40afa56df8facb0ac2c83		
Warnings:					
Information:					
10	NPL Documents	Kimura- Vascular Endothelial Growth Factor or Antagonist Reduces Brain Edema Formation.pdf	406388	no	6
			d3d9ea0af814aa6ddccd4d5574099b78e966ca97		
Warnings:					
Information:					
11	NPL Documents	Ozaki- Blockade of Vascular Endothelial Cell Growth Factor Receptor Signaling Is Sufficient to Completely. pdf	996852	no	11
			7d4b9dd39ef3a324e9324cd02bc5d0117dbf7f0d1		
Warnings:					
Information:					
12	NPL Documents	Pisano-Undersulfated Low-Molecular Weight Glycol Split Heparin as an Antiangiogenic VEGF. pdf	269484	no	6
			7c3c57f390310118efd138d2fe3e7766470364b2		
Warnings:					
Information:					
13	NPL Documents	Schuch- In Vivo Administration of Vascular Endothelial Growth Factor-VEGF and its Antagonist.pdf	2310962	no	7
			64bbdb02016418eb5abfd579644c62d54a88c958		
Warnings:					
Information:					
14	NPL Documents	Siemeister- An Antagonistic Vascular Endothelial Growth Factor-VEGF-Variant Inhibits VEGV.pdf	245096	no	5
			d964ff178fd21106334ff9f0426b15fa21a7d498		
Warnings:					
Information:					
15	NPL Documents	Soker- Inhibition of Vascular Endothelial Growth Factor-VEGF-induced Endothelial Cell.pdf	176362	no	7
			e0e225f6ad627ff1de17ca35f73301841485da79		
Warnings:					
Information:					
16	NPL Documents	RH01-704-032009-OA.pdf	3439732	no	27
			909358d8aed3a8a7cd8fbad553dd7d25d20ab716		
Warnings:					
Information:					
17	NPL Documents	RH01-702-061009-FOA.pdf	887444	no	7
			13748400ea8c90950851f4d9d3889de0d83f56d7		

<b>Warnings:</b>					
<b>Information:</b>					
18	NPL Documents	RH01-704-110409-FOA.pdf	1447723	no	13
			ba216d5b3f74e80f7a7a1d26f1124c6a83e3e6b3		
<b>Warnings:</b>					
<b>Information:</b>					
19	NPL Documents	RH01-702-122409-OA.pdf	1203530	no	10
			897f49d1e5d4084150ad98b57ca8d8fe9e4930bd		
<b>Warnings:</b>					
<b>Information:</b>					
20	NPL Documents	ZHANG-AngiogenicInhibitionMediated byaDNAzymeThatTargetsVascu- lar.pdf	2039680	no	7
			9d4911ae297cb19a883beb4a7353fa6c2e1813a7		
<b>Warnings:</b>					
<b>Information:</b>					
21	Fee Worksheet (PTO-875)	fee-info.pdf	29856	no	2
			a808bfc5af250d6d124f34bebe9bc3347dde82c		
<b>Warnings:</b>					
<b>Information:</b>					
<b>Total Files Size (in bytes):</b>			18716557		
<p><b>This Acknowledgement Receipt evidences receipt on the noted date by the USPTO of the indicated documents, characterized by the applicant, and including page counts, where applicable. It serves as evidence of receipt similar to a Post Card, as described in MPEP 503.</b></p> <p><b><u>New Applications Under 35 U.S.C. 111</u></b>  <b>If a new application is being filed and the application includes the necessary components for a filing date (see 37 CFR 1.53(b)-(d) and MPEP 506), a Filing Receipt (37 CFR 1.54) will be issued in due course and the date shown on this Acknowledgement Receipt will establish the filing date of the application.</b></p> <p><b><u>National Stage of an International Application under 35 U.S.C. 371</u></b>  <b>If a timely submission to enter the national stage of an international application is compliant with the conditions of 35 U.S.C. 371 and other applicable requirements a Form PCT/DO/EO/903 indicating acceptance of the application as a national stage submission under 35 U.S.C. 371 will be issued in addition to the Filing Receipt, in due course.</b></p> <p><b><u>New International Application Filed with the USPTO as a Receiving Office</u></b>  <b>If a new international application is being filed and the international application includes the necessary components for an international filing date (see PCT Article 11 and MPEP 1810), a Notification of the International Application Number and of the International Filing Date (Form PCT/RO/105) will be issued in due course, subject to prescriptions concerning national security, and the date shown on this Acknowledgement Receipt will establish the international filing date of the application.</b></p>					